SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...

Several headwinds are impacting the company, including generic competition for its blockbuster drug Stelara, the ongoing talc lawsuit (which could see a final decision in the first half of the ...

Overall, global Stelara sales dropped 14.7% year-over-year to roughly $2.3 billion in 2024’s fourth quarter. For the full 12-month earnings period, Stelara sales slipped around 4.6% to $10.4 ...

Investors are watching biosimilar competition with immunology drug Stelara, which extended to the key US market in January. We assume a more than $3 billion decline in global Stelara sales in 2025.

Using a single PBM as the sole distribution channel is unprecedented. Without a lot of fanfare or a news release, Wezlana (ustekinumab-auub), the first Stelara (ustekinumab) biosimilar has hit the ...

Noteably, Pyzchiva joins Wezlana (ustekinumab-auub) in the interchangeability club, making them the only 2 ustekinumab biosimilars able to be switched in for the reference product at the pharmacy ...

Ustekinumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Psoriatic Arthritis. According to GlobalData, Pre-Registration drugs for Psoriatic Arthritis ...

Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the ...

Will the Stelara biosimilars be a reprise of the Humira biosimilars in 2023 and be slow to catch on? Biosimilar watchers circled 2023 as a red-letter year because that was the year that the Humira ...

Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 which play an important role in inflammatory and immune responses. The approval is based on a ...